JUNIPER PHARMACEUTICALS, INC. (NASDAQ:JNP) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Item5.02.

On December19, 2016, Juniper Pharmaceuticals, Inc. (the Company)
entered into an employment agreement (the Employment Agreement)
with Jeffrey Young, to which Mr.Young will serve as the Companys
new Vice President, Finance, Chief Financial Officer and
Treasurer, effective January1, 2017.

Mr.Young brings over 20 years of financial leadership in the life
sciences sector to Juniper, most recently serving as Chief
Financial Officer and Treasurer of OvaScience, a global fertility
company focused on new treatment options for women, which he
joined in September 2014. Before OvaScience, Mr.Young served as
Chief Financial Officer and Treasurer of Transmedics,Inc. from
August 2013 to August 2014, leading the finance, accounting, tax
and treasury functions. Prior to Transmedics, Mr.Young was Chief
Financial Officer and Treasurer at Lantheus Medical Imaging,Inc.,
an international corporation, from September 2008 to August 2013.
While at Lantheus, he was responsible for multiple functions,
including finance, accounting, customer service, tax and
treasury. Before Lantheus, Mr.Young served as Chief Accounting
Officer, Vice President of Finance and Treasurer at Critical
Therapeutics from 2005 to 2008, and managed the companys
transition during its acquisition by Cornerstone BioPharma.
Earlier in his career, Mr.Young held finance roles at
PerkinElmer,Inc. and PricewaterhouseCoopersLLP. Mr.Young is a
Certified Public Accountant and holds a B.S. in Business
Administration from Georgetown University.

to the terms of the Employment Agreement, Mr.Youngs annual base
salary will be $355,000. He will also be eligible to receive a
target annual bonus equal to 45% of his base salary, as then in
effect, as determined by the board of directors. The Company will
also pay Mr.Young a sign on bonus of $45,000 following the
commencement of his employment with the Company. Mr.Young will
also be entitled to participate in the Companys stock option
plan, as in effect from time to time, and will receive an initial
option award (the Option Award), effective January3, 2017 (the
Date of Grant), to purchase 170,000 shares of the Companys common
stock, which option will have an exercise price equal to the
closing price on the Date of Grant, have a life of seven years
and vest at the rate of one-quarter per year on each of the first
four anniversaries of the Date of Grant. The Option Award is
intended to qualify as an employment inducement grant under
NASDAQ Listing Rule 5635(c)(4). Upon approval by the Board of
Directors, Mr.Young will also be entitled to participate in the
Companys performance share program, and will receive an initial
grant of 25,000 performance-based restricted stock units. He will
also be eligible to participate in all employee benefit programs
generally available to other executive level employees of the
Company.

Mr.Young will succeed George O. Elston as Chief Financial
Officer, Principal Financial Officer, and Treasurer of the
Company. In connection with his departure, which is effective
December31, 2016, and subject to his execution of a general
release and separation agreement in favor of the Company,
Mr.Elston is entitled to severance compensation in accordance
with the terms of his employment agreement providing for
compensation in the event of his termination by the Company
without cause, as described in the Companys definitive proxy
statement filed with the Securities and Exchange Commission on
June22, 2016. The terms of Mr.Elstons employment agreement also
include provisions concerning non-competition and
indemnification, and covenants not to solicit any employee of the
Company, and to cooperate with the Company.

The foregoing are only brief descriptions of the material terms
of the Employment Agreement and the Option Award, and do not
purport to be complete descriptions of the rights and obligations
of the parties thereunder, and are qualified in their entirety by
reference to the full text of the Employment Agreement and the
form of Option Award, which are filed as Exhibit 10.1 and 10.2,
respectively, to this Current Report on Form 8-K and incorporated
herein by reference.

On December20, 2016, the Company issued a press release entitled
Juniper Pharmaceuticals Announces Appointment of Jeffrey Young as
Chief Financial Officer, announcing that Mr.Young will be joining
the Company as its new Chief Financial Officer to succeed George
O. Elston. A copy of the press release is furnished and attached
as Exhibit 99.1 hereto and is incorporated herein by reference.

The information being furnished to Item7.01 of this Current
Report on Form 8-K and contained in Exhibit 99.1 shall not be
deemed to be filed for purposes of Section18 of the Exchange Act
of 1934, as amended (the Exchange Act), or otherwise subject to
the liability of that section, and shall not be incorporated by
reference into any registration statement or other document filed
under the Securities Act of 1933, as amended, or the Exchange
Act, except as shall be expressly set forth by specific reference
in such filing.

About JUNIPER PHARMACEUTICALS, INC. (NASDAQ:JNP)

Juniper Pharmaceuticals, Inc., formerly Columbia Laboratories, Inc., is a women’s health therapeutic company focused on developing intra-vaginal therapeutics that addresses the medical needs in women’s health. The Company operates through two segments: product and service. The product segment includes supply chain management for CRINONE. The product segment also includes the royalty stream the Company receives from Allergan for CRINONE sales in the United States, as well as the development of new product candidates. The service segment includes pharmaceutical development, clinical trial manufacturing and advanced analytical and consulting services for the its customers, as well as characterizing and developing pharmaceutical product candidates for its internal programs, and managing the preclinical and clinical manufacturing of COL-1077 and its intra-vaginal ring (IVR). Its product and product development programs include CRINONE 8%, COL-1077, JNP-0101, JNP-0101 and JNP-0301.

JUNIPER PHARMACEUTICALS, INC. (NASDAQ:JNP) Recent Trading Information

JUNIPER PHARMACEUTICALS, INC. (NASDAQ:JNP) closed its last trading session up +0.20 at 5.35 with 189,833 shares trading hands.